Kiniksa Pharmaceuticals develops and sells ARCALYST, a treatment for recurrent pericarditis and other inflammatory conditions. Analyst consensus is Strong Buy, based on the latest ratings from 3 firms (3 buy, 0 hold, 0 sell). In the past 30 days there were 2 dark pool prints.
Analyst Ratings & Price Targets
Analyst Ratings →| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Oct 28 | Goldman Sachs | Target raised | Buy | |
| Oct 28 | Wedbush | Target raised | Buy | |
| Oct 28 | Wells Fargo | Maintained | Buy | |
| Jul 30 | Goldman Sachs | Target raised | Buy | |
| Jul 29 | JP Morgan | Maintained | Buy |
Whale Options Flow
90DNo whale options trades in KNSA in the last 90 days.
Dark Pool
30DAI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether KNSA is in one of them and how their past KNSA trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered KNSA in an article yet. Here's the latest on the wider market.
About Kiniksa Pharmaceuticals International
Kiniksa Pharmaceuticals is a drug developer based in London that focuses on cardiovascular diseases. Its main product, ARCALYST, is approved in the United States for recurrent pericarditis, an inflammatory condition of the heart lining, and for certain autoinflammatory syndromes. The company sells ARCALYST in the United States through specialty pharmacies, has licensed partners in other regions, and is developing KPL-387, an investigational antibody that targets the same inflammation pathway. Its customers are patients and the doctors who treat them.
- Headquarters
- London